In the lead-up to the November midterm elections, President Donald Trump has emphasized his administration’s efforts to lower prescription drug prices as a key achievement that should appeal to voters. However, many Americans, particularly in Florida’s Seventh Congressional District, report little relief from rising health care costs, despite these initiatives.

The district, located in the northeast suburbs of Orlando and known for its Republican leanings, includes a mix of entrepreneurs, early retirees, and gig workers who often lack employer-sponsored insurance. Residents in the area describe ongoing struggles with the affordability of both prescription drugs and health insurance premiums, undermining the perceived impact of the president’s policies.

James Evans, a 37-year-old real estate agent in the district, expressed skepticism about the effectiveness of the administration’s approach. Without insurance for most medications, he worries a serious medical diagnosis could lead to financial ruin. “I don’t see how this is going to affect most Americans on the daily,” Evans said, citing continued increases in overall health care expenses despite some drug prices falling.

The district also has one of the highest enrollments nationwide in Affordable Care Act (ACA) plans, a number that recently declined by 11 percent amid the lapse of pandemic-era subsidies. Additionally, Florida remains one of ten states that have not expanded Medicaid eligibility, leaving many lower-income residents uninsured. This gap complicates access to affordable care for many.

Residents like Emily Bellairs-Romero, a 57-year-old with Crohn’s disease, reported steep increases in medication costs, rising from $60 to $3,400 annually after insurance changes. Her family’s situation is further complicated by her early retirement due to health issues and her husband’s planned retirement, which threatens to eliminate their employer-based insurance coverage before she qualifies for Medicare. “Health insurance is drowning us,” she said.

Similarly, Lorraine Little, a 64-year-old retiree, shared that her ACA premiums have ballooned—from $208 a month to $345—and she has had to switch from a prescribed blood thinner to aspirin because of cost. Local health insurance agents have noted that workers laid off in recent corporate downsizings face daunting choices between expensive ACA plans and cheaper but inadequate short-term plans that may exclude preexisting conditions.

The Trump administration has launched several initiatives to reduce drug costs, including negotiating deals with pharmaceutical companies, introducing a website designed to help consumers locate lower prices, and a program allowing Medicare beneficiaries to pay a capped monthly rate for certain medications. White House officials assert these steps have saved many Americans money, pointing to over a million Medicare enrollees benefiting from reduced prices for obesity drugs, with collective savings of $470 million. However, critics note that these savings do not extend to most Americans who are not enrolled in Medicare, and many lower-income Medicaid recipients already face minimal prescription costs.

Political figures reflect the divide over health care's role in the midterms. Republican organizers commend the efforts to align U.S. drug prices with those of other wealthy nations, framing it as part of an “America First” agenda. Meanwhile, Democratic candidates in the district emphasize the persistent high costs faced by voters. Bale Dalton, a former NASA chief of staff and Navy veteran running for Congress, has made reducing health care expenses central to his campaign, highlighting stories from constituents who struggle to afford necessary medications.

Dalton acknowledges the intent behind the president’s drug pricing initiatives but stresses that many voters have yet to experience tangible benefits. He pointed to his own family’s experience, which includes limited coverage for certain costly treatments, and said that despite the high cost risks, some choose to forgo insurance due to unaffordability.

As the election approaches, the question remains whether the administration’s drug pricing efforts will translate into meaningful relief for voters grappling with broader health care expenses or if these issues will continue to shape the political landscape in districts like Florida’s Seventh.